Viscosupplementation – Literature Review of Recent Studies

Marcus Vinicius Danieli*, João Paulo Fernandes Guerreiro and Alexandre de Oliveira Queiroz
Uniort. E Orthopaedic Hospital, Londrina, Paraná, Brazil

*Corresponding Author: Marcus Vinicius Danieli, Uniort. E Orthopaedic Hospital, Londrina, Paraná, Brazil.

Received: March 12, 2018; Published: May 23, 2018

Abstract
Viscosupplementation, or intra-articular application of Hyaluronate, is a treatment indicated for patients with chondral injuries. However, even with strongly supported results, some studies and guidelines, such as the American Academy of Orthopedic Surgeons (AAOS) of 2013, discourage its use in clinical practice, giving as argument the lack of evidence. This literature review of recent articles will show that viscosupplementation has good indications of use, with scientific basis, mainly for active patients with mild to moderate knee arthritis, below 60 years old.

Keywords: Hyaline Cartilage; Injuries; Osteoarthritis; Viscossupplementation; Knee

Viscosupplementation, or intra-articular application of Hyaluronate, is a treatment indicated for patients with chondral injuries, more studied for knee joints use. However, it may be indicated in other joints such as ankle, hip and carpal, for example, however, with less evidence.

Studies show that intra-articular hyaluronic acid has the effect of decreasing chondral volume loss and preserving cartilage [1]. It also improves chondral integrity and decreases the formation of osteophytes, showing a deceleration of evolution to osteoarthritis [2]. These effects may also be demonstrated in magnetic resonance imaging, where it may lead to cartilage signal changes, for better, after the use of the medication [3].

It has also been demonstrated action in pain by anti-inflammatory effect and improvement of synovial fluid quality [2]. In this way it can be indicated even in initial chondral injuries because it is a safe, persistent and effective method [4-6].

Nowadays there is also indication for advanced arthrosis (classified as Kellgren and Lawrence degrees III and IV), because it may not improve articular function significantly in these cases, but it has an effect on pain reduction and, consequently, on the improvement of quality of life [4,7]. However, more recent studies suggest that the use of this treatment in more severe cases of osteoarthritis or obese patients may compromise its outcome [8,9]. Ricci, et al. [10] suggest that the best response to treatment occurs in patients under 60 years of age. And Henrotin, et al. [5] suggest that the best outcome occurs in mild to moderate degrees of knee arthrosis.

Recent study reports that hyaluronic acid has an important modulating action, mainly through the interaction with CD44 receptors present in fibroblast-like type B synoviocytes [2,4]. Therefore, in addition to the mechanical effects of promoting better distribution of forces, reducing pressure by weight and recovering the rheological properties of synovial fluid, hyaluronic acid also acts biochemically, decreasing the gene expression of cytokines and enzymes associated with osteoarthritis [4,7,11]. From the economic point of view, there is an increasing number of studies showing that, if incorporated into the treatment of knee osteoarthritis, viscosupplementation may be cost-effective and may even delay the progression to a total knee replacement surgery [5-7,11-13]. This delay in the evolution to surgery was proven by studies involving the analysis of a large number of cases [14-16].

Citation: Marcus Vinicius Danieli., et al. "Viscosupplementation – Literature Review of Recent Studies". EC Orthopaedics 9.6 (2018): 372-375.
Viscosupplementation – Literature Review of Recent Studies

Other treatment options failure should not be expected before indicating the viscosupplementation because it is known that the patients who will benefit most from this treatment are those with a lower degree of osteoarthritis and more active use of the joints [11].

However, even with strongly supported results, some studies and guidelines, such as the American Academy of Orthopedic Surgeons (AAOS) of 2013, discourage its use in clinical practice, giving as argument the lack of evidence. Even so, other guidelines from other societies, such as the American Medical Society for Sports Medicine (AMSSM) and ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) strongly recommend the use of viscosupplementation, stating that such use is safe, with guaranteed effect up to 6 months after application [7,17,18]. The recommendation is that this treatment should be applied with the care of being individualized for each patient [17]. In addition, articles and authors criticize the method as the AAOS guideline was developed, citing that the articles used were not the best basis of evidence, and articles using the same criteria have recently reached different results [19,20].

The different molecular weight, of each type of hyaluronic acid, makes its result vary per the research. Studies suggest that products with molecular weights greater than 3000 kDa have better efficacy and fewer adverse effects than products weighing less than 3000 kDa [21]. The great problem of articles and literature reviews is to be able to compare different types of drugs, with different types of obtaining and molecular weights.

In addition, viscosupplementation studies still differ as to the type and degree of chondral injury, patients age, number of applications, and interval between doses [22-24].

He., et al. [25]. in a meta-analysis comparing the effect of hyaluronic acid application against triamcinolone application showed that the corticosteroid has a better effect in the first month, however the effect of the medications equals at 3 months and hyaluronic acid has a better effect with 6 months after application. Thus, the best indication would be to apply the association of these drugs. This 6 months of effect duration is confirmed by other recent studies [26,27], as well as its superiority to triamcinolone and saline when it was used as placebo [29]. But there are some articles, in a small number, but also with strong evidence, which do not confirm the superiority of viscosupplementation when compared to placebo [22,30-32]. As a critique, many of these studies mix patients with different degrees of disease, different age groups and degree of activity. It should be noted here that even studies not funded by the pharmaceutical industry show that viscosupplementation has a better effect than placebo [33].

A Cochrane review has shown that viscosupplementation has rather great benefits when compared to placebo in relation to pain, function, and quality of life scores. Based on Grades of Recommendation Assessment, Development and Evaluation (GRADE), viscosupplementation for knee arthrosis leads to pain reduction and improved function with low risk of adverse effects. It is a viable option for young patients with not so severe disease, and future research is needed to evaluate the use in more advanced osteoarthritis, which molecular weight is more effective, if the cross-link preparations have a better effect, evaluate effect duration, safety and economic analysis of treatment [24].

Different guidelines with recommendation and no recommendation for viscosupplementation have disrupted the medical conducts, and it should be reaffirmed that the treatment of arthrosis should be individualized for each patient [23].

In this way, the use of this treatment should be part of the arsenal of the doctor who treats patients with chondral injuries. This is a difficult to treat pathology that causes a great loss of quality of life, and should be attacked with all available therapeutic methods, to avoid more aggressive and costly procedures, such as surgeries.

Conclusion

In conclusion, it is suggested that viscosupplementation should be used in patients with mild to moderate knee arthrosis (until Kellgren and Lawrence degree III), active, non-obese (by the BMI criterion), below 60 years old (relative indication, because the biological age of the patient should be assessed) associated with other forms of conservative treatment, such as physiotherapy, analgesics, muscle strengthening, change of lifestyle habits, etc. It is advisable to associate triamcinolone in the dose of 40 mg with the application to improve the results. In patients who do not fit these indications, it is suggested, if any type of intra-articular medication is indicated, the use of triamcinolone alone in the dose of 40 mg, which could be repeated every 3 months.

Viscosupplementation – Literature Review of Recent Studies

Bibliography


Viscosupplementation – Literature Review of Recent Studies


Volume 9 Issue 6 June 2018
©All rights reserved by Marcus Vinicius Danieli, et al.